Is it common to misclassify a small lung biopsy (e.g., an 11 mm, low‑differentiated lesion staged T1aN0M0) as a neuroendocrine tumor (NET) instead of small‑cell carcinoma on histology?

Is Histologic Misclassification Between NET and Small Cell Carcinoma Common?

Yes, distinguishing between well-differentiated neuroendocrine tumors (carcinoids) and small cell carcinoma on small lung biopsies is a recognized diagnostic challenge, particularly when specimens are limited, crushed, or poorly preserved. However, with proper use of Ki-67 proliferation index and careful attention to morphologic criteria, this distinction can usually be made accurately 1, 2.

Key Diagnostic Challenges in Small Biopsies

The difficulty arises primarily in small biopsy specimens where:

• Typical and atypical carcinoids cannot be reliably distinguished from each other in small biopsies or cytology 1
• Crush artifact in small specimens can obscure nuclear details needed to count mitoses accurately 2
• Necrotic or poorly preserved tissue makes morphologic assessment difficult 1

The Critical Distinguishing Tool: Ki-67 Proliferation Index

Ki-67 immunostaining is the most valuable tool for distinguishing small cell carcinoma from carcinoid tumors in limited biopsy material 1, 3:

• Small cell carcinoma (SCLC): Ki-67 typically 50-100% (often >70%) 3, 2
• Carcinoid tumors (typical/atypical): Ki-67 typically 5-15% (usually <20%) 3

This dramatic difference in proliferation index provides objective data when mitotic counting is unreliable due to specimen limitations 1.

Morphologic Features to Assess

When adequate tissue is available, key distinguishing features include:

Small Cell Carcinoma (SCLC):

• Mitotic count: >10 mitoses per 2 mm² field 2
• Small cells (2-3× lymphocyte size) with scant cytoplasm 3
• High nuclear-to-cytoplasmic ratio 3, 2
• Nuclear molding and chromatin smearing 3
• Absent or inconspicuous nucleoli 2
• Extensive necrosis 3

Carcinoid Tumors:

• Typical carcinoid: 0-1 mitoses per 2 mm² field 2
• Atypical carcinoid: 2-10 mitoses per 2 mm² field 2
• Relatively bland, uniform cytology 3
• Moderate granular cytoplasm 3
• Finely granular chromatin 3
• Only punctate necrosis (in atypical carcinoid) 3

Common Pitfalls and How to Avoid Them

Pitfall #1: Intermediate/Combined Variants

Small cell carcinoma can have intermediate morphologic features that overlap with large cell neuroendocrine carcinoma or even appear more "carcinoid-like" 4, 5. Combined SCLC (with ≥10% non-small cell component) may be missed on small biopsies 3, 4.

Solution: When morphology is ambiguous, always perform Ki-67 staining 1.

Pitfall #2: Counting Mitoses Near Diagnostic Cutoffs

When mitotic counts fall near the cutoffs of 2 or 10 per 2 mm² field, count at least three separate 2 mm² fields and use the calculated mean rather than the single highest count 2.

Solution: In crushed or necrotic specimens where accurate mitotic counting is impossible, Ki-67 is essential 1, 2.

Pitfall #3: Neuroendocrine Marker Expression

Up to 25% of carcinoids may be negative for cytokeratin (AE1/AE3), while these markers are consistently positive in SCLC 1. Additionally, fewer than 10% of SCLCs are negative for all neuroendocrine markers 2.

Solution: Use a panel of neuroendocrine markers (chromogranin A, synaptophysin, CD56/NCAM) rather than relying on a single marker 1, 2, 6, 1.

Clinical Context Matters

In your specific scenario—an 11 mm, poorly differentiated T1aN0M0 lesion—several factors increase diagnostic accuracy:

• The small size and early stage (T1aN0M0) would be unusual for SCLC, which typically presents with extensive disease 7, 8
• "Poorly differentiated" terminology suggests high-grade features more consistent with SCLC than carcinoid 1
• If Ki-67 shows >50%, this strongly favors SCLC over carcinoid 1, 3, 2

Practical Recommendation

For any small lung biopsy with neuroendocrine morphology where the distinction between carcinoid and small cell carcinoma is uncertain, pathologists should routinely perform Ki-67 immunostaining 1, 2. This single test provides the most reliable objective criterion for classification when tissue is limited. If the initial pathology report lacks Ki-67 data and the diagnosis impacts treatment decisions (which it absolutely does—carcinoids are treated surgically while SCLC receives chemotherapy), request Ki-67 staining on the existing biopsy material before proceeding with definitive therapy 1.

Expert pathology review is recommended for problematic cases, as interobserver agreement exceeds 95% when strict morphologic criteria are applied to adequate specimens 3.